JNJ vs MRK
Johnson & Johnson and Merck & Co. Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | JNJ | MRK |
|---|---|---|
| Revenue | $94.2B | $65.0B |
| Net income | $26.8B | $18.3B |
| Gross margin | 67.9% | 74.8% |
| Net margin | 28.5% | 28.1% |
| Return on equity | — | 36.9% |
| Diluted EPS | $11.03 | $7.28 |
| Dividend / share | $5.14 | $3.28 |
| Payout ratio | — | 44.8% |
| Free cash flow | $19.7B | $12.4B |
| Equity | — | $52.6B |
| Net debt / equity | — | 0.66× |
| Current ratio | 1.03× | 1.54× |
| Revenue CAGR 5y | 2.7% | 9.4% |
| Profit CAGR 5y | 12.7% | 20.9% |
JNJ bills 1.4× the revenue of MRK, and keeps more of each dollar of revenue as profit (28.5% against 28.1%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | JNJ | MRK |
|---|---|---|
| FY2025 | $94.2B | $65.0B |
| FY2024 | $88.8B | $64.2B |
| FY2023 | $85.2B | $60.1B |
| FY2022 | $80.0B | $59.3B |
| FY2021 | $78.7B | $48.7B |
| FY2020 | $82.6B | $41.5B |
| FY2019 | $82.1B | $39.1B |
| FY2018 | $81.6B | $42.3B |
| FY2017 | $76.5B | $40.1B |
| FY2016 | $71.9B | $39.8B |
Net income by year
Bottom line
| Fiscal year | JNJ | MRK |
|---|---|---|
| FY2025 | $26.8B | $18.3B |
| FY2024 | $14.1B | $17.1B |
| FY2023 | $35.2B | $365.0M |
| FY2022 | $17.9B | $14.5B |
| FY2021 | $20.9B | $13.0B |
| FY2020 | $14.7B | $7.1B |
| FY2019 | $15.1B | $9.8B |
| FY2018 | $15.3B | $6.2B |
| FY2017 | $1.3B | $2.4B |
| FY2016 | $16.5B | $3.9B |
Advertisement
AdSense · Rectangle 336×280